Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.69 |
| ▸ | PDE5A | O76074 | 3/20 | 0.53 |
| ▸ | TRIM58 | Q8NG06 | 3/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | CLK3 | P49761 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16638699 | 0.83 | EGLN1 (0.77) | EGLN1PDE5ATRIM58HTR3AHRH4 | |
| SCHEMBL621862 | 0.82 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL27919427 | 0.81 | EGLN1 (0.70) | EGLN1PDE5AADORA2AHTR3AHRH4 | |
| SCHEMBL16626157 | 0.81 | EGLN1 (0.66) | EGLN1ADORA2AGBA1 | |
| SCHEMBL626406 | 0.81 | EGLN1 (0.70) | EGLN1PDE5AADORA2AGBA1HTR3A | |
| SCHEMBL21802969 | 0.77 | EGLN1 (0.64) | EGLN1PDE5ATRIM58HIF1ACLK4 | |
| SCHEMBL627205 | 0.77 | EGLN1 (0.69) | EGLN1ADORA2ADYRK1A | |
| SCHEMBL16626248 | 0.76 | EGLN1 (0.66) | EGLN1TRIM58ADORA2A | |
| SCHEMBL16626188 | 0.76 | EGLN1 (0.66) | EGLN1 | |
| SCHEMBL628374 | 0.75 | EGLN1 (0.69) | EGLN1PDE5AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| US-20180148435-A9 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-31 | — | — | US | disclosed |
| US-20170320859-A1 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9573940-B2 | 4-aminoquinazolinyl-2-yl-1-pyrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-21 | — | — | US | disclosed |
| US-20150197507-A1 | 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-16 | — | — | US | disclosed |
| US-20140309215-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARAMCEUTICA NV (BE) | 2014-10-16 | — | — | US | disclosed |
| US-8796263-B2 | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| EP-2603502-A1 | 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-06-19 | — | — | EP | disclosed |
| US-20130143871-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-06 | — | — | US | disclosed |
| WO-2012021830-A1 | 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320859-A1 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885PDE5A 175/4885TRIM58 3154/4885 |
| US-20180148435-A9 | 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885PDE5A 175/4885TRIM58 3154/4885 |
| US-20140309215-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 7/4885PDE5A 397/4885TRIM58 3684/4885 |
| US-20150197507-A1 | 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885PDE5A 168/4885TRIM58 3586/4885 |
| US-10246442-B2 | 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885PDE5A 175/4885TRIM58 3154/4885 |
| US-20130143871-A1 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | EGLN1 7/4885PDE5A 397/4885TRIM58 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.